Submitted:
08 July 2026
Posted:
13 July 2026
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Study Design and Setting
4.2. Study Population
4.3. Data Collection
- -
- Demographic characteristics (age and sex);
- -
- Comorbidities (including cardiovascular disease, diabetes, chronic kidney disease, and others);
- -
- Microbiological etiology (based on blood cultures and/or intraoperative samples);
- -
- Valve involvement (native or prosthetic) and location;
- -
- Echocardiographic findings, including vegetation size;
- -
- Embolic and other complications (e.g., stroke and systemic embolism);
- -
- Management strategy (including antimicrobial therapy and surgical intervention);
- -
- Clinical outcomes (including in-hospital mortality and one-year survival); and
- -
- Outcomes.
4.4. Statistical Analysis
4.5. Ethics
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Chen, H.; Zhan, Y.; Zhang, K.; Gao, Y.; Chen, L.; Zhan, J.; Chen, Z.; Zeng, Z. The Global, Regional, and National Burden and Trends of Infective Endocarditis From 1990 to 2019: Results From the Global Burden of Disease Study 2019. Front. Med. 2022, 9, 774224. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.K.; Hassan, S.M.A.; Côté, M.; Leis, B.; Yanagawa, B. Current trends and challenges in infective endocarditis. Curr. Opin. Cardiol. 2024, 40, 75–84. [Google Scholar] [CrossRef] [PubMed]
- Calinoiu, A.; Guluta, E.-C.; Rusu, A.; Minca, A.; Minca, D.; Tomescu, L.; Gheorghita, V.; Minca, D.G.; Negreanu, L. Accessory renal arteries - a source of hypertension: A case report. World J. Clin. Cases 2023, 11, 1506–1512. [Google Scholar] [CrossRef] [PubMed]
- Epidemiological Profile and Mortality of Infective Endocarditis Over the Past Decade: A Systematic Review and Meta-Analysis of 133 Studies - PubMed [Internet]. 30 Mar 2026. Available online: https://pubmed.ncbi.nlm.nih.gov/40015544/ (accessed on 30 Mar 2026).
- Tzoumas, A.; Sagris, M.; Xenos, D.; Ntoumaziou, A.; Kyriakoulis, I.; Kakargias, F.; Liaqat, W.; Nagraj, S.; Patel, R.; Korosoglou, G.; et al. Epidemiological Profile and Mortality of Infective Endocarditis Over the Past Decade: A Systematic Review and Meta-Analysis of 133 Studies. Am. J. Cardiol. 2025, 244, 67–88. [Google Scholar] [CrossRef] [PubMed]
- Raad, I.I.; Hanna, H.A. Intravascular Catheter-Related Infections. Arch. Intern. Med. 2002, 162, 871–878. [Google Scholar] [CrossRef] [PubMed]
- Infective Endocarditis: Background, Pathophysiology, Etiology [Internet]. 30 Mar 2026. Available online: https://emedicine.medscape.com/article/216650-overview (accessed on 30 Mar 2026).
- Burban, A.; Słupik, D.; Reda, A.; Szczerba, E.; Grabowski, M.; Kołodzińska, A. Novel Diagnostic Methods for Infective Endocarditis. Int. J. Mol. Sci. 2024, 25, 1245. [Google Scholar] [CrossRef] [PubMed]
- Fourré, N.; Zimmermann, V.; Senn, L.; Monney, P.; Tzimas, G.; Tagini, F.; Tozzi, P.; Kirsch, M.; Guery, B.; Papadimitriou-Olivgeris, M. Comparison of the 2023 ISCVID and ESC Duke clinical criteria for the diagnosis of infective endocarditis among patients with positive blood cultures for new typical microorganisms. Infection 2025, 53, 1393–1401. [Google Scholar] [CrossRef] [PubMed]
- Lau, L.; Baddour, L.; Hidalgo, N.F.; Brothers, T.D.; Kong, W.K.F.; A Borger, M.; Duval, X.; Tribouilloy, C.; Obadia, J.-F.; Golian, M.; et al. Infective endocarditis: it takes a team. Eur. Hear. J. 2025, 46, 2275–2288. [Google Scholar] [CrossRef] [PubMed]
- Novelli, A.; Ingason, A.B.; Jirka, C.; Callas, P.; Hirashima, F.; Lovoulos, C.; Dauerman, H.L.; Polomsky, M. Impact of the COVID-19 Pandemic on Infective Endocarditis Management and Outcomes: Analysis of a National Clinical Database. Am. J. Cardiol. 2023, 209, 224–231. [Google Scholar] [CrossRef] [PubMed]
- Mincă, A.; I Mincă, D.; Calinoiu, A.L.; Gheorghiță, V.; Popescu, C.C.; Rusu, A.; Cristea, A.M.; Mincă, D.G. Myasthenia Gravis Triggered by a COVID-19 Infection: A Case Report and Literature Review. Cureus 2024, 16, e59538. [Google Scholar] [CrossRef] [PubMed]
- Hayley, B.; Chan, K.L. Infectious CompLications in Infective Endocarditis. In Infective Endocarditis: Epidemiology, Diagnosis, Imaging, Therapy, and Prevention [Internet]; Springer: Cham, 2016; pp. 123–36. [Google Scholar] [CrossRef]
- Bishev, D.; DiCaro, M.V.; Chakraborty, S.; Stanger, G.-T.; Ho, C.; Tak, T. Infective Endocarditis and Complications; Surgical Indications and Management: An Integrative Review. J. Pers. Med. 2026, 16, 103. [Google Scholar] [CrossRef] [PubMed]
- Hutt, E.; Canosa, F.J.M.; Unai, S.; Jaber, W.A. Manifestations of Prosthetic Valve Endocarditis: Lessons From Multimodality Imaging and Pathological Correlation. Circ. Cardiovasc. Imaging 2024, 17, e016435. [Google Scholar] [CrossRef] [PubMed]
- Santos-Patarroyo, S.D.; Quintero-Martinez, J.A.; Lahr, B.D.; Chesdachai, S.; Abu Saleh, O.; Michelena, H.I.; Villarraga, H.R.; DeSimone, D.C.; Baddour, L.M. Correlation Between Blood Culture Time to Positivity and Vegetation Size in Staphylococcus aureus Infective Endocarditis. Antibiotics 2025, 14, 456. [Google Scholar] [CrossRef] [PubMed]
- Rajani, R.; Klein, J.L. Infective endocarditis: A contemporary update. Clin. Med. 2020, 20, 31–35. [Google Scholar] [CrossRef] [PubMed]
- Menon, T. Uncommon pathogens causing infective endocarditis. Indian J. Thorac. Cardiovasc. Surg. 2023, 40, 8–15. [Google Scholar] [CrossRef] [PubMed]
- DeSimone, D.C.; Garrigos, Z.E.; Marx, G.E.; Tattevin, P.; Hasse, B.; McCormick, D.W.; Hannan, M.M.; Zuhlke, L.J.; Radke, C.S.; Baddour, L.M.; et al. Blood Culture–Negative Endocarditis: A Scientific Statement From the American Heart Association. J. Am. Hear. Assoc. 2025, 14, e040218. [Google Scholar] [CrossRef] [PubMed]
- D’alonzo, M.; Di Bacco, L.; Fiore, A.; Baudo, M.; Zanin, F.; Baldelli, C.; Moini, C.; Folliguet, T.; Muneretto, C. The Dilemma of Surgical Timing in Acute Aortic Valve Endocarditis: Does Early Surgery Improve Risks or Prognosis? J. Cardiovasc. Dev. Dis. 2025, 12, 153. [Google Scholar] [CrossRef] [PubMed]
- Arregle, F.; Martel, H.; Philip, M.; Gouriet, F.; Casalta, J.P.; Riberi, A.; Torras, O.; Casalta, A.-C.; Camoin-Jau, L.; Lavagna, F.; et al. Infective endocarditis with neurological complications: Delaying cardiac surgery is associated with worse outcome. Arch. Cardiovasc. Dis. 2021, 114, 527–536. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Kim, J.B.; Sastry, B.K.S.; Chen, M. Infective endocarditis. Lancet 2024, 404, 377–392. [Google Scholar] [CrossRef] [PubMed]

| Variable | Pandemic (n=47) | Post-pandemic (n=53) | p-value |
|---|---|---|---|
| Demographics | |||
| Age, years, median (IQR) | 68 (62–72) | 68 (58–74) | 0.853 |
| Male sex, n (%) | 31 (68.9) | 35 (71.4) | 0.824 |
| Urban residence, n (%) | 19 (42.2) | 24 (49.0) | 0.540 |
| Previous IE, n (%) | 3 (6.7) | 1 (2.0) | 0.346 |
| Clinical presentation | |||
| Sepsis criteria, n (%) | 4 (8.9) | 6 (12.2) | 0.742 |
| Positive blood cultures, n (%) | 27 (60.0) | 32 (65.3) | 0.671 |
| Type of infective endocarditis | |||
| Native valve IE, n (%) | 28 (62.2) | 32 (65.3) | 0.831 |
| Prosthetic valve IE, n (%) | 9 (20.0) | 4 (8.2) | 0.136 |
| Device-related IE, n (%) | 6 (13.3) | 5 (10.2) | 0.753 |
| Type of acquisition | |||
| Community-acquired, n (%) | 26 (57.8) | 36 (73.5) | 0.130 |
| Healthcare-associated, n (%) | 14 (31.1) | 11 (22.4) | 0.361 |
| Mixed acquisition, n (%) | 0 (0.0) | 1 (2.0) | 1.000 |
| Portal of entry | |||
| Cutaneous, n (%) | 6 (13.3) | 11 (22.4) | 0.293 |
| Digestive, n (%) | 4 (8.9) | 9 (18.4) | 0.238 |
| Oral/ENT, n (%) | 4 (8.9) | 10 (20.4) | 0.152 |
| Pulmonary, n (%) | 1 (2.2) | 0 (0.0) | 0.479 |
| Unknown portal, n (%) | 21 (46.7) | 19 (38.8) | 0.532 |
| Aetiology | |||
| Staphylococci, n (%) | 13 (27.7) | 11 (20.8) | |
| Enterococci, n (%) | 6 (12.8) | 9 (17.0) | |
| Streptococci, n (%) | 7 (14.9) | 9 (17.0) | |
| Fungi (Candida), n (%) | 2 (4.3) | 2 (3.8) | |
| Other, n (%) | 6 (12.8) | 5 (9.4) | |
| Unknown (negative BC), n (%) | 13 (27.7) | 17 (32.1) | |
| Echocardiography | |||
| TEE performed, n (%) | 33 (73.3) | 44 (89.8) | 0.059 |
| Local cardiac complications | |||
| Any complication, n (%) | 8 (17.8) | 15 (30.6) | 0.160 |
| Perivalvular abscess, n (%) | 4 (8.9) | 13 (26.5) | 0.033 |
| Valve perforation, n (%) | 3 (6.7) | 1 (2.0) | 0.346 |
| Prosthetic dehiscence, n (%) | 1 (2.2) | 0 (0.0) | 0.479 |
| Prosthetic leak, n (%) | 0 (0.0) | 1 (2.0) | 1.000 |
| Peripheral embolism | |||
| Any embolism, n (%) | 17 (37.8) | 31 (63.3) | 0.023 |
| Central nervous system, n (%) | 3 (6.7) | 16 (32.7) | 0.002 |
| Spleen, n (%) | 6 (13.3) | 9 (18.4) | 0.581 |
| Osteoarticular, n (%) | 3 (6.7) | 9 (18.4) | 0.124 |
| Kidney, n (%) | 2 (4.4) | 9 (18.4) | 0.053 |
| Lung, n (%) | 2 (4.4) | 6 (12.2) | 0.271 |
| Treatment and outcomes | |||
| Time to diagnosis, days, median (IQR) | 40 (30–54) | 24 (13.8–36.3) | <0.01 |
| Antibiotic duration, days, median (IQR) | 42 (35–46) | 42 (30–42) | 0.347 |
| Length of hospital stay, days, median (IQR) | 39 (24–52) | 40 (29–46) | 0.932 |
| Surgery indicated, n (%) | 33 (73.3) | 43 (87.8) | 0.114 |
| Surgery performed, n/N (%) | 26/33 (78.8) | 29/43 (67.4) | 1.000 |
| In-hospital mortality, n (%) | 24 (51.1) | 13 (24.5) | 0.007 |
| Survival, n (%) | 23 (48.9) | 40 (75.5) | 0.007 |
| Recurrence, n (%) | 2 (4.4) | 2 (4.1) | 1.000 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).